Welcome to our dedicated page for Minerva Neurosci SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Minerva Neurosciences, Inc. (Nasdaq: NERV) SEC filings page on Stock Titan consolidates the company’s regulatory documents from EDGAR with AI-powered summaries to help readers interpret complex disclosures. As a clinical-stage biopharmaceutical company focused on central nervous system (CNS) diseases, Minerva uses its SEC reports to describe the status of its lead drug candidate roluperidone for negative symptoms of schizophrenia, its MIN-301 program for Parkinson’s disease, and the financial resources supporting these efforts.
In annual reports on Form 10-K and quarterly reports on Form 10-Q, Minerva provides audited and interim financial statements, research and development and general and administrative expense details, information about its liability related to the sale of future royalties, and discussion of risks associated with clinical development and regulatory review. These filings also reference the Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for the roluperidone New Drug Application and the requirement for a confirmatory Phase 3 trial.
Current reports on Form 8-K capture material events such as the October 2025 securities purchase agreement for Series A Convertible Preferred Stock and warrants, the related private placement financing of up to $200 million in gross proceeds, and the appointment of new directors and consulting arrangements tied to roluperidone’s Phase 3 program. Definitive proxy statements on Schedule 14A outline proposals for stockholder votes, including increases in authorized common stock, approval of common shares issuable upon conversion of the Series A Preferred Stock, and amendments to the company’s equity incentive plan.
On Stock Titan, each 10-K, 10-Q, 8-K, DEF 14A and related document is accompanied by AI-generated highlights that explain key points in plain language, such as how Minerva plans to use proceeds from financings, how it describes the design of its confirmatory trial, and what changes are proposed to its capital structure. Real-time updates from EDGAR and easy access to insider- and governance-related disclosures allow users to review Minerva’s regulatory history and understand how clinical, financial and corporate decisions are documented over time.
Minerva Neurosciences (NERV) announced a private placement of up to $200 million, comprising 80,000 shares of Series A Convertible Preferred Stock at $1,000 per share ($80 million upfront) and warrants for additional preferred shares. Tranche A warrants are immediately exercisable for 80,000 Series A Preferred shares for cash ($80 million) until the tenth day after a public announcement of a statistically significant Phase 3 primary endpoint at 12 weeks. Tranche B warrants cover 40,000 preferred shares ($40 million), allow cashless exercise starting on the earlier of the milestone announcement or three years after closing, and expire four years after closing.
Conversion to common stock requires stockholder approval, after which each preferred share converts at a $2.11 per‑share conversion price, subject to a 9.99% beneficial ownership cap. If stockholder approval is not obtained within one year, the preferred shares are subject to redemption at the defined Liquidation Preference. Warrants may be forfeited if an investor engages in Short Sales within 48 months after closing. The company plans to use proceeds to fund the roluperidone Phase 3 confirmatory trial, NDA resubmission, U.S. launch readiness if approved, and for working capital.
The company agreed to file an S-3 resale registration after stockholder approval, expand the Board by up to three Vivo Capital designees, and form a scientific advisory board for the Phase 3 program.